
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is expected to see continued positive growth in their PYLARIFY and DEFINITY platforms, supported by the company's strong sales management and continued adoption of their products. PYLARIFY will continue with its smooth transition to its new formulation, TruVu, and the company is well-positioned for future growth with a strong pipeline of new products awaiting FDA approval. While risks related to reimbursement and regulation are present, the company's management has maintained a solid financial outlook for 2026 and beyond, mitigating concerns about potential disruptions to their business operations.
Bears say
Lantheus Holdings is heavily reliant on its pipeline of diagnostic agents and strategic partnerships, particularly for Alzheimer's disease, for future growth. However, the availability of therapeutic agents may affect the commercialization of these diagnostics, and it remains to be seen if these diagnostic agents will be positively received by the market. While the company's first quarter results were strong, management's cautious guidance for the rest of the year demonstrates potential hurdles and limits the potential for significant short-term gains.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares